Back to News
Market Impact: 0.4
Astrazeneca's breast cancer drug fails late-stage trial
Source: reuters.com
Healthcare & BiotechCompany Fundamentals
AstraZeneca said its breast-cancer drug failed to meet the primary endpoint of improving progression-free survival in a late-stage trial. The failure materially weakens the drug's clinical and commercial outlook and could pressure AstraZeneca shares.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
strongly negative
Sentiment Score
-0.55
Ticker Sentiment
AZN-0.85
More News
- AstraZeneca breast cancer drug fails late-stage trial goal
- Novartis investors turn spotlight on M&A after trial setbacks
- Nvidia in talks to invest up to $10 billion in Anthropic IPO
- The inside story on the historic U.S.-Venezuela oil deal and how it will work
- Apollo in talks to buy J&J orthopedics unit for nearly $20 billion
- Exclusive-Nvidia in talks to invest in Anthropic’s mega IPO, sources say